The study will examine the safety and efficacy of using ExaStim paired with rehabilitation therapy for patients living with upper extremity paralysis due to spinal cord injuries.
ExaStim delivers stimulation to the spinal cord to modulate neural networks, enabling improved motor functions. Some research suggests that noninvasive spinal cord stimulation can help spinal cord injury patients regain motor function, according to a Feb. 2 press release.
The clinical trial will enroll up to 140 patients at 14 sites across the U.S. The ExaStim neurostimulator received FDA breakthrough device designation status.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.